Cover2 Resources

In our last episode of this series, we learned how passage of the Ensuring Patient Access and Effective Drug Enforcement Act took away the DEA’s most effective diversion control enforcement tool, the immediate suspension order. The bill was shaped in large part by a former DEA lawyer. On this episode, you’ll hear more stories about Congressman and high ranking government agency officials who have played key roles in deciding the fate of drug bills and policies; and weeks later went to work in the pharmaceutical industry. 24 years ago, the medical director for the FDA played a key role in approving OxyContin without clinical trials and shortly thereafter, left to go to work for Purdue Pharma. In this podcast you’ll hear a clip from “The Sentence that Helped Set Off the Opioid Crisis” a podcast by Caitlin Esch and Krissy Clark in their “Uncertain Marketplace” series that frames a key reason why OxyContin was approved by the FDA and the people involved in that decision. Back in 2007, a member of Congress led